<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/05301658-E204-428F-A5F5-3BA794DECB49"><gtr:id>05301658-E204-428F-A5F5-3BA794DECB49</gtr:id><gtr:name>Danish Cancer Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1A60B063-E58F-4072-A2EA-8474BE302464"><gtr:id>1A60B063-E58F-4072-A2EA-8474BE302464</gtr:id><gtr:name>International Agency for Research on Cancer (IARC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/03A5EBD8-AA65-4691-AF2A-77134D4166A1"><gtr:id>03A5EBD8-AA65-4691-AF2A-77134D4166A1</gtr:id><gtr:name>European ScreeningPort (ESP)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E3FF571C-4ECF-478A-AA19-5F68DA0D9627"><gtr:id>E3FF571C-4ECF-478A-AA19-5F68DA0D9627</gtr:id><gtr:name>University of Zurich</gtr:name><gtr:address><gtr:line1>71,Raemistrasse</gtr:line1><gtr:line4>Zurich</gtr:line4><gtr:line5>CH 8006</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8601BFF2-0736-45CD-A9C3-077182D588F7"><gtr:id>8601BFF2-0736-45CD-A9C3-077182D588F7</gtr:id><gtr:name>Claude Bernard University Lyon 1 (UCBL)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/767C83D0-2A56-4E64-BF98-B8F6933A9AF8"><gtr:id>767C83D0-2A56-4E64-BF98-B8F6933A9AF8</gtr:id><gtr:name>Evotec</gtr:name><gtr:address><gtr:line1>114 Milton Park
Abingdon</gtr:line1><gtr:city>Oxford</gtr:city><gtr:postCode>OX14 4SA</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/05301658-E204-428F-A5F5-3BA794DECB49"><gtr:id>05301658-E204-428F-A5F5-3BA794DECB49</gtr:id><gtr:name>Danish Cancer Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1A60B063-E58F-4072-A2EA-8474BE302464"><gtr:id>1A60B063-E58F-4072-A2EA-8474BE302464</gtr:id><gtr:name>International Agency for Research on Cancer (IARC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/03A5EBD8-AA65-4691-AF2A-77134D4166A1"><gtr:id>03A5EBD8-AA65-4691-AF2A-77134D4166A1</gtr:id><gtr:name>European ScreeningPort (ESP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E3FF571C-4ECF-478A-AA19-5F68DA0D9627"><gtr:id>E3FF571C-4ECF-478A-AA19-5F68DA0D9627</gtr:id><gtr:name>University of Zurich</gtr:name><gtr:address><gtr:line1>71,Raemistrasse</gtr:line1><gtr:line4>Zurich</gtr:line4><gtr:line5>CH 8006</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8601BFF2-0736-45CD-A9C3-077182D588F7"><gtr:id>8601BFF2-0736-45CD-A9C3-077182D588F7</gtr:id><gtr:name>Claude Bernard University Lyon 1 (UCBL)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A60007FB-4A48-4A5F-B298-1EF14314EF76"><gtr:id>A60007FB-4A48-4A5F-B298-1EF14314EF76</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801936"><gtr:id>8BA48013-A5AB-4680-919A-AF7585861E84</gtr:id><gtr:title>Mechanisms of endogenous antigen processing by the MHC class II pathway: studies with viral and cellular proteins</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801936</gtr:grantReference><gtr:abstractText>The immune system?s T cells recognise short protein fragments of proteins (called epitopes) that are made by various processing pathways and then displayed on the surface of the body?s cells. If a cell is infected with a virus or is cancerous then epitopes from viral or cancer-specific cellular proteins are displayed. T cells specific for these epitopes can then destroy the affected cell. Vaccines and immunotherapies are being developed that aim to harness T cells to selectively destroy virus-infected or cancerous cells in this way. It therefore becomes important to understand the processing pathways how epitopes are made, since these control the supply and composition of the epitopes displayed on the cell surface. 

To study how epitopes are made from proteins found in different locations within cells I have used Epstein-Barr virus (EBV) as a model. I have made T cells specific for different types of EBV protein and used these to study processing. This virus is associated with several different cancers therefore the lessons learnt from this system have direct medical impact as well as teaching us more about the immune system in general. I have found that some proteins are transferred between cells before processing while others are processed within the cell itself even though these are all located in the same cellular compartment, the nucleus. Furthermore my work also suggests that proteins within the nucleus are unavailable for processing by an important internal processing pathway called macro-autophagy. Here I intend to continue working in the EBV system to learn more about the rules governing how proteins are processed within cells. I will then extend the work to study how cellular proteins expressed in cancer cells are processed and in turn recognised by T cells and how these processes differ from viral proteins. Finally, I will study a range of inherited fatal neurological conditions, including Huntington?s disease, caused by proteins that form toxic aggregates. These aggregates may be cleared by some of the processing pathways and I wish to establish whether the rules learned from the EBV system will apply here also, whether nuclear-localised aggregates, like EBNA1, evade processing by macro-autophagy and if an alternative pathway called chaperone mediated autophagy can compensate.</gtr:abstractText><gtr:technicalSummary>While exogenously-acquired proteins are the main source of antigens presented to CD4+ T cells, it is known that many proteins expressed endogenously within MHC class II-positive cells can also access the MHC II presentation pathway. This proposal seeks to further our understanding of different pathways that govern the processing of such proteins, in particular the influence that intracellular location might have on processing route. 

Firstly, I plan to build on my recent work studying the processing for CD4+ T cell recognition of Epstein-Barr virus (EBV) antigens within EBV-transformed lymphoblastoid cell lines (LCLs). I have CD4+ T cell clones to a range of epitopes in the virus-coded nuclear antigens EBNAs, in the latent membrane proteins LMPs 1 and 2, and in a cytoplasmic protein BHRF1 now known to be a latent cycle antigen. Our evidence shows that EBNA 2 and the EBNA3 proteins are processed via the inter-cellular transfer of as-yet-poorly-defined antigenic species, whereas EBNA1, the LMPs and BHRF1 are processed by different intracellular pathways. We have found that nuclear-localised EBNA1 is only processed by the intracellular macro-autophagy (MA) pathway when it is experimentally relocalised into the cytoplasm. The work will focus on determining the relative importance of MA, chaperone-mediated autophagy (CMA) and plasma membrane recycling to the endo/lysosome system as MHC II access routes for these proteins, and the effect of antigen or epitope re-location on that process. 

Secondly, I shall move on to study the processing of cellular proteins of medical importance. I will investigate the processing of WT1 and STEAP, two tumour-associated antigens expressed in a wide range of malignancies that are good CD4 targets and compare their processing with the EBV proteins. I will go on to study antigen processing in the context of neurological diseases caused by poly-glutamine (polyQ) containing proteins forming toxic aggregates within cells. Degradative pathways such as MA, which can clear such aggregates, are of interest as potential therapeutic interventions for such conditions. In animal models disease severity is reduced when naturally nuclear-resident polyQ proteins are relocalised out of the nucleus. The objective will be to test the notion that MA cannot clear nuclear-localised aggregates and determine whether CMA can act as a substitute pathway to clear nuclear-localised aggregates.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>430382</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Molecular and Cellular Biology</gtr:department><gtr:description>EU ITN</gtr:description><gtr:id>AC3DD218-6011-4221-BB8E-393CD849EE6E</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Agency for Research on Cancer (IARC)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EU ITN</gtr:description><gtr:id>F8FCE3C2-A557-4C24-A657-4BDC40068286</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Danish Cancer Society</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Centre for Genotoxic Stress Research</gtr:department><gtr:description>EU ITN</gtr:description><gtr:id>3FC8527C-D57E-4EAD-BD7C-509CA03F3460</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich (Universit?t Z?rich UZH)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Institute of Experimental Immunology</gtr:department><gtr:description>EU ITN</gtr:description><gtr:id>96F53EA9-FC60-491C-A809-EDFC2391D421</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich (Universit?t Z?rich UZH)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Institute of Experimental Immunology</gtr:department><gtr:description>Christian Munz</gtr:description><gtr:id>55EE42F4-D10F-470B-A374-968F2E4DF929</gtr:id><gtr:impact>Blood. 2013 Feb 28;121(9):1584-94. doi: 10.1182/blood-2012-08-450775. Epub 2013 Jan 7.
Leung CS, Maurer MA, Meixlsperger S, Lippmann A, Cheong C, Zuo J, Haigh TA, Taylor GS, M&amp;uuml;nz C. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205. Blood. 2013 Feb 28;121(9):1584-94. doi: 10.1182/blood-2012-08-450775.</gtr:impact><gtr:partnerContribution>Access to humanised mouse models to measure vaccine efficacy</gtr:partnerContribution><gtr:piContribution>Supplied expertise and reagents for key experiments pertaining to development of vaccine candidates to prevent human disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European ScreeningPort (ESP)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EU ITN</gtr:description><gtr:id>9D533516-4486-48EA-90B2-5FD745F64017</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Immunology and Inflammation</gtr:department><gtr:description>EU ITN</gtr:description><gtr:id>FB6E8ABB-9D06-4841-80B8-B19455E44845</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Claude Bernard University Lyon 1 (UCBL)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Cancer Research Centre of Lyon (CRCL)</gtr:department><gtr:description>EU ITN</gtr:description><gtr:id>FCBD6F2A-99A1-4A17-BAE0-B05E0E0E1C71</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Evotec</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EU ITN</gtr:description><gtr:id>36CBDCE2-D900-4D0A-9113-DC51FEC68885</gtr:id><gtr:impact>Multi disciplinary aspects:
virology, immunology, cell biology, drug discovery. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:impact><gtr:partnerContribution>Partners bring complementary expertise in a range of oncogenic human viruses, macroautophagy and drug discovery approaches.</gtr:partnerContribution><gtr:piContribution>I co-founded a European-wide supra-disciplinary network consisting of nine partners (four academic, two private sector, one non-profit, four academic) to develop next generation anti-viral compounds that leverage nucleocytoplasmic shuttling and macroautophagy. The science underpinning this application is from my MRC-funded research. 

The network applied for a EU ITN award which was scored highly and is likely to be funded in the present funding round.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Science Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C45881F4-4844-43E5-AC7D-EA0FD70D9551</gtr:id><gtr:impact>30 members of the public visited the research laboratories, were given a presentation of the work performed, and taken for a guided tour of the laboratories to observe practical demonstrations.

Enhanced public awareness of the role of research performed in the centre.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>46000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Agents Committee</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>E1031026-A8FE-4927-A00B-F89B2B002219</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>281000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>328D1FA8-9A3E-4D3C-A5C7-9770E6A2C20E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>197261</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant (wellcome MS grant)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>7614FDCD-3D42-4421-A227-7578B79644BC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A61B4F3B-5954-4B24-A579-DF77A82819A0"><gtr:id>A61B4F3B-5954-4B24-A579-DF77A82819A0</gtr:id><gtr:title>Nuclear shelter: the influence of subcellular location on the processing of antigens by macroautophagy.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4298f1bc9f22f8a025503bb4fb95d22e"><gtr:id>4298f1bc9f22f8a025503bb4fb95d22e</gtr:id><gtr:otherNames>Leung CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDA4A1AD-3C50-4564-8772-7596C45A9AD8"><gtr:id>CDA4A1AD-3C50-4564-8772-7596C45A9AD8</gtr:id><gtr:title>CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc17541961a574382f3fd6e17b82a408"><gtr:id>dc17541961a574382f3fd6e17b82a408</gtr:id><gtr:otherNames>Long HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80554539-E78F-430B-A46F-39F3F7505E0B"><gtr:id>80554539-E78F-430B-A46F-39F3F7505E0B</gtr:id><gtr:title>Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4298f1bc9f22f8a025503bb4fb95d22e"><gtr:id>4298f1bc9f22f8a025503bb4fb95d22e</gtr:id><gtr:otherNames>Leung CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB74A5F6-38FF-4A3F-A0AC-984E5822F05C"><gtr:id>FB74A5F6-38FF-4A3F-A0AC-984E5822F05C</gtr:id><gtr:title>Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV.</gtr:title><gtr:parentPublicationTitle>Cancer letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/166a20a6643c8b0f6a06763c1896dc84"><gtr:id>166a20a6643c8b0f6a06763c1896dc84</gtr:id><gtr:otherNames>Taylor GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0304-3835</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F26E270-670D-45CA-9791-0ACEE5A179EB"><gtr:id>6F26E270-670D-45CA-9791-0ACEE5A179EB</gtr:id><gtr:title>The immunology of Epstein-Barr virus-induced disease.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/166a20a6643c8b0f6a06763c1896dc84"><gtr:id>166a20a6643c8b0f6a06763c1896dc84</gtr:id><gtr:otherNames>Taylor GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/39C0C943-2A69-48B0-85E0-2A9C4B6EAF17"><gtr:id>39C0C943-2A69-48B0-85E0-2A9C4B6EAF17</gtr:id><gtr:title>Immune defence against EBV and EBV-associated disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc17541961a574382f3fd6e17b82a408"><gtr:id>dc17541961a574382f3fd6e17b82a408</gtr:id><gtr:otherNames>Long HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A694947B-668D-499D-BBD9-5C836C15A0BD"><gtr:id>A694947B-668D-499D-BBD9-5C836C15A0BD</gtr:id><gtr:title>The role of tetraspanin CD63 in antigen presentation via MHC class II.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f994e37a1370e2c93d16c9c21badff6"><gtr:id>5f994e37a1370e2c93d16c9c21badff6</gtr:id><gtr:otherNames>Petersen SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/664461DA-D4B1-4A77-A814-593D6E58DA1B"><gtr:id>664461DA-D4B1-4A77-A814-593D6E58DA1B</gtr:id><gtr:title>Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72d96a4bcbdce942d350d62e762139ba"><gtr:id>72d96a4bcbdce942d350d62e762139ba</gtr:id><gtr:otherNames>Zuo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE49A129-5F6C-456B-BDC8-9822A524647F"><gtr:id>DE49A129-5F6C-456B-BDC8-9822A524647F</gtr:id><gtr:title>T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07b8d4142566ff4f71445dc7321a60f1"><gtr:id>07b8d4142566ff4f71445dc7321a60f1</gtr:id><gtr:otherNames>Mackay LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B01D7CE9-EAAB-4861-B27F-ED2771967ED1"><gtr:id>B01D7CE9-EAAB-4861-B27F-ED2771967ED1</gtr:id><gtr:title>A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/83450e7665f631915c019eeb9d0218d3"><gtr:id>83450e7665f631915c019eeb9d0218d3</gtr:id><gtr:otherNames>Fox CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0BE7A170-68F1-40A6-AE6B-EA479CB6CBDC"><gtr:id>0BE7A170-68F1-40A6-AE6B-EA479CB6CBDC</gtr:id><gtr:title>Autophagy and immunity - insights from human herpesviruses.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8105854f6c79083a9dd41b0f14d6395f"><gtr:id>8105854f6c79083a9dd41b0f14d6395f</gtr:id><gtr:otherNames>Williams LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3D74DAD3-94A4-49EF-9489-B19039F8C430"><gtr:id>3D74DAD3-94A4-49EF-9489-B19039F8C430</gtr:id><gtr:title>T-Cell Responses to EBV.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de54615df428affa046bc044ae8d9416"><gtr:id>de54615df428affa046bc044ae8d9416</gtr:id><gtr:otherNames>Hislop AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0070-217X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/318B81EF-EF36-4777-B3D4-FF082DDF89F2"><gtr:id>318B81EF-EF36-4777-B3D4-FF082DDF89F2</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE68CAAC-A80E-46FD-AB74-D0816E44DB39"><gtr:id>FE68CAAC-A80E-46FD-AB74-D0816E44DB39</gtr:id><gtr:title>Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4298f1bc9f22f8a025503bb4fb95d22e"><gtr:id>4298f1bc9f22f8a025503bb4fb95d22e</gtr:id><gtr:otherNames>Leung CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801936</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>